Solomon David A, Kim Jung-Sik, Waldman Todd
Department of Pathology, University of California, San Francisco, San Francisco, CA 94143, United States.
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC 20057, United States.
BMB Rep. 2014 Jun;47(6):299-310. doi: 10.5483/bmbrep.2014.47.6.092.
Cohesin is a multi-protein complex composed of four core subunits (SMC1A, SMC3, RAD21, and either STAG1 or STAG2) that is responsible for the cohesion of sister chromatids following DNA replication until its cleavage during mitosis thereby enabling faithful segregation of sister chromatids into two daughter cells. Recent cancer genomics analyses have discovered a high frequency of somatic mutations in the genes encoding the core cohesin subunits as well as cohesin regulatory factors (e.g. NIPBL, PDS5B, ESPL1) in a select subset of human tumors including glioblastoma, Ewing sarcoma, urothelial carcinoma, acute myeloid leukemia, and acute megakaryoblastic leukemia. Herein we review these studies including discussion of the functional significance of cohesin inactivation in tumorigenesis and potential therapeutic mechanisms to selectively target cancers harboring cohesin mutations.
黏连蛋白是一种由四个核心亚基(SMC1A、SMC3、RAD21以及STAG1或STAG2)组成的多蛋白复合体,负责在DNA复制后姐妹染色单体的黏连,直至有丝分裂期间其裂解,从而使姐妹染色单体能够准确分离到两个子细胞中。最近的癌症基因组学分析发现,在包括胶质母细胞瘤、尤因肉瘤、尿路上皮癌、急性髓系白血病和急性巨核细胞白血病在内的特定人类肿瘤子集中,编码核心黏连蛋白亚基以及黏连蛋白调节因子(如NIPBL、PDS5B、ESPL1)的基因存在高频体细胞突变。在此,我们综述这些研究,包括讨论黏连蛋白失活在肿瘤发生中的功能意义以及选择性靶向携带黏连蛋白突变癌症的潜在治疗机制。